|
注册号: Registration number: |
ChiCTR2500106712 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-29 09:28:37 |
|
注册时间: Date of Registration: |
2025-07-29 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
骨膜下种植体治疗牙列缺失患者的探索性研究 |
|
Public title: |
An exploratory study on the treatment of patients with dentition loss using subperiosteal implants |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
骨膜下种植体治疗牙列缺失伴颌骨重度缺损患者的单臂探索性研究 |
|
Scientific title: |
Subperiosteal implants for dentition loss with severe jaw defect: a single-arm, exploratory study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
邹多宏 |
研究负责人: |
邹多宏 |
|
Applicant: |
Duohong Zou |
Study leader: |
Duohong Zou |
|
申请注册联系人电话: Applicant telephone: |
+86 13601645549 |
研究负责人电话:
Study leader's |
+86 13601645549 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zouduohongyy@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zouduohongyy@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市黄浦区瞿溪路500号 |
研究负责人通讯地址: |
上海市黄浦区制造局路639号 |
|
Applicant address: |
No. 500, Quxi Road, Huangpu District, Shanghai |
Study leader's address: |
Zhizaoju Road 639,Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海交通大学医学院附属第九人民医院 |
||
|
Applicant's institution: |
The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |
||
|
研究负责人所在单位: |
上海交通大学医学院附属第九人民医院 |
||
|
Affiliation of the Leader: |
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SH9H-2024-T509-1 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院附属第九人民医院研究者发起的临床研究伦理审查专委会 |
||
|
Name of the ethic committee: |
Ethics Review Committee for clinical research initiated by researchers |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-01-09 00:00:00 | ||
|
伦理委员会联系人: |
甄红 |
||
|
Contact Name of the ethic committee: |
Zhen Hong |
||
|
伦理委员会联系地址: |
上海市黄浦区制造局路639号 |
||
|
Contact Address of the ethic committee: |
Zhizaoju Road 639,Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 23271699 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
shjyiec@126.com |
|
研究实施负责(组长)单位: |
上海交通大学医学院附属第九人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市黄浦区制造局路639号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Zhizaoju Road 639,Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
self-funding |
||||||||||||||||||||||
|
研究疾病: |
牙齿缺失 |
||||||||||||||||||||||
|
Target disease: |
Tooth loss |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
探索骨膜下种植体治疗牙列缺失伴颌骨重度缺损患者的安全性和有效性 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore the safety and efficacy of subperiosteal implants in the treatment of patients with dentition loss accompanied by severe jawbone defects |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.全口有明显口腔脓肿、癌前病变、真菌感染和智齿冠周炎; 2.存在以下任何心脏临床症状或疾病: 6个月内有心肌梗死或心衰发作史;静息状态心电图检查发现有重要临床意义的异常(如心率、传导、形态特征等异常)或完全性左束支传导阻滞或三级心脏传导阻滞或二级心脏传导阻滞或PR间期> 250 ms;存在增加QTc延长、心率异常风险的因素,如心力衰竭、低钾血症、先天性长QT综合征、长QT综合征家族史或有40岁以下直系亲属不明原因猝死、或有延长QT间期伴随用药。 3. 3个月内有脑血管意外的患者; 4.手术当天的血压>=180/110mmHg; 5.有凝血功能障碍、血小板减少症、血友病或显著贫血; 6.糖化血红蛋白>10%; 7.有静脉使用双磷酸盐史; 8.使用免疫抑制剂者; 9.恶性肿瘤未经规范治疗,或经过规范治疗后未满5年; 10. 被诊断为获得性免疫缺陷综合征、梅毒、乙肝和丙肝,未规范治疗和控制者; 11.经研究者判断,患者有其他可能影响研究结果或导致本研究被迫中途终止的因素,如怀孕、哺乳期、酗酒、药物滥用、其他的严重疾病(含精神疾病)需要合并治疗,有严重的实验室检查异常,伴有家庭或社会等因素,会影响到患者的安全。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Obvious oral abscesses, precancerous lesions, fungal infections and wisdom tooth pericoronitis in the whole mouth; 2. Presence of any of the following cardiac clinical symptoms or diseases: History of myocardial infarction or heart failure within 6 months; resting state ECG examination finds important clinically significant abnormalities (such as abnormalities in heart rate, conduction, morphological characteristics, etc.) or complete left bundle branch block or third-degree heart block or second-degree heart block or PR interval > 250 ms; There are factors that increase the risk of QTc prolongation and abnormal heart rate, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or sudden unexplained death of an immediate family member under 40 years of age, or concomitant medication for prolonged QT interval. 3. Patients with cerebrovascular accident within 3 months; 4. Blood pressure on the day of surgery>=180/110mmHg; 5. Coagulation dysfunction, thrombocytopenia, hemophilia or significant anemia; 6. Glycated hemoglobin > 10%; 7. History of intravenous bisphosphonate use; 8. Those who use immunosuppressants; 9. Malignant tumors have not been treated standardly, or less than 5 years after standardized treatment; 10. Diagnosed with acquired immunodeficiency syndrome, syphilis, hepatitis B and hepatitis C without standardized treatment and control; 11. According to the investigator's judgment, the patient has other factors that may affect the results of the study or lead to the forced termination of this study, such as pregnancy, lactation, alcoholism, drug abuse, other serious diseases (including mental illness) that require combined treatment, serious laboratory test abnormalities, accompanied by family or social factors and other factors, which will affect the safety of the patient. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-03-04 00:00:00 至 To 2026-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
国家生物信息中心 China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/),在试验结束6个月时间内上传 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
National Center for Bioinformation China National Center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/), uploaded within 6 months of the end of the trial |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case record form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |